At the news
? BEARISHIMPACT 6/10 8-K filed May 13, 2026 at 16:33 ET
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 development, while reporting a Q1 2026 net loss of $115.3M (largely non-cash fair value charges) and cash of only $4.8M pre-loan. The loan extends runway but adds significant leverage, and the company's ability to achieve Phase 3 milestones remains uncertain given ongoing cash burn.
- Entered $25M secured term loan with Innoviva at 14.0% interest, maturing January 11, 2029
- Q1 2026 net loss of $115.3M vs $6.5M in Q1 2025, driven by $101M non-cash change in convertible loan fair value
- Cash and cash equivalents of $4.8M at March 31, 2026, down from $8.7M at December 31, 2025
- Operating loss widened to $8.8M from $8.2M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access